浙江联盛化学股份有限公司 关联交易决策制度 第二条 公司关联交易应当定价公允、审议程序合规、信息披露规范。公司 应当积极通过有效方式减少关联交易。 第二章 关联人及关联交易认定 第三条 公司的关联人包括关联法人和关联自然人。 第四条 具有下列情形之一的法人或其他组织，为公司的关联法人： （一）直接或者间接控制公司的法人或者其他组织； 浙江联盛化学股份有限公司 关联交易决策制度 第一章 总 则 第一条 为规范浙江联盛化学股份有限公司（以下简称"公司"）关联交易行 为，提高公司规范运作水平，保护公司和全体股东的合法权益，根据《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第7号—— 交易与关联交易》等法律、法规、规范性文件以及《浙江联盛化学股份有限公司 章程》（以下简称《公司章程》）等规定，制定本制度。 浙江联盛化学股份有限公司 关联交易决策制度 （二）公司董事、监事及高级管理人员； （二）由前项所述法人直接或者间接控制的除公司及其控股子公司以外的法 人或者其他组织； （三）由本制度第五条所列公司的关联自然人直接或者间接控制的，或者担 任董事（独立董事除外）、高级管理人员的，除公司及其控 ...

Financial Performance - In 2023, the company achieved an operating revenue of 662.02 million yuan, a decrease of 36.41% compared to the previous year[4]. - The net profit attributable to the parent company was 71.13 million yuan, down 61.13% year-on-year[4]. - The company's operating revenue for 2023 was ¥662,015,730.44, a decrease of 36.41% compared to ¥1,041,133,695.75 in 2022[17]. - The net profit attributable to shareholders for 2023 was ¥71,112,773.72, down 61.13% from ¥182,965,402.93 in 2022[17]. - The basic and diluted earnings per share for 2023 were both ¥0.66, a decline of 64.32% from ¥1.85 in 2022[17]. - The gross profit margin for the fine chemical sector was 19.08%, down 5.15% from the previous year[74]. - The company reported a total operating cost of ¥535,696,699.55, which is a decrease of 32.09% year-on-year[74]. - The sales volume of fine chemicals decreased by 4.80% to 48,796.61 tons in 2023[75]. Market Conditions - The decline in performance was primarily due to the impact of the macroeconomic environment, with weak demand and intensified competition in the chemical industry[4]. - In 2023, the chemical industry overall saw a revenue decline of 2.7% to ¥9.27 trillion and a profit drop of 31.2% to ¥486.26 billion[28]. - The pesticide price index dropped to 80.19 points, a significant decline of 48.0% year-on-year, with 92% of pesticide products experiencing price decreases[34]. - The global market for wet electronic chemicals is dominated by traditional companies from Europe and the U.S., holding approximately 32% market share[38]. - Domestic companies in China hold less than 5% of the global market share for wet electronic chemicals, despite recent breakthroughs in electronic-grade chemicals[38]. Strategic Initiatives - The company plans to focus on its core business, enhance product quality through R&D and technological upgrades, and strengthen market expansion efforts[4]. - The company aims to extend its BDO industrial chain into ultra-pure electronic chemicals and biodegradable new materials to strengthen its position in the specialty fine chemical sector[42]. - The company is focused on expanding its product offerings in the fine chemical sector, particularly in pharmaceutical intermediates and electronic chemicals, which are critical for emerging industries[29]. - The company plans to expand its electronic chemicals business and enhance its high-end manufacturing capabilities through various R&D projects[84]. - The company aims to implement effective cost management mechanisms across production, R&D, procurement, and operations to control expenses and improve efficiency[122]. Research and Development - The company has made significant investments in R&D, forming strategic partnerships with various academic institutions to enhance its technological capabilities[58]. - The company’s R&D investment amounted to ¥25,566,012.19 in 2023, representing 3.86% of operating revenue, an increase from 3.16% in 2022[86]. - The number of R&D personnel increased by 12.50% to 54, with the proportion of R&D personnel in the total workforce rising to 12.76%[86]. - The company is developing new technologies for NMP synthesis, with pilot tests completed and expected to enhance competitiveness and energy efficiency[83]. - The company has completed small-scale tests for several R&D projects, aiming to enhance product competitiveness and reduce costs[85]. Cash Flow and Investments - The net cash flow from operating activities increased significantly to ¥193,755,940.16, compared to a negative cash flow of ¥5,026,134.96 in 2022, representing a 3,954.97% increase[17]. - The total cash inflow from investment activities surged by 14,067.49% to ¥627,305,399.15, attributed to the redemption of large fixed-term deposits and increased spending on fundraising projects[87]. - The net cash flow from financing activities decreased by 106.10% to -¥40,396,813.98, mainly due to the previous year's public stock issuance[87]. - The company has a remaining balance of RMB 41,543.95 million in raised funds, with RMB 38,000.00 million allocated to purchase large certificates of deposit[108]. Governance and Compliance - The company has established a comprehensive governance structure in place, adhering to relevant laws and regulations to ensure transparency and accountability[142]. - The company has a dedicated team responsible for information disclosure, ensuring timely and accurate communication with stakeholders[148]. - The company has maintained a clean record with zero significant or important defects in non-financial reporting[198]. - The board of directors consists of 8 members, including 3 independent directors, and held 6 meetings during the reporting period to make informed decisions[145]. - The company emphasizes the protection of minority shareholders' rights and provides opportunities for them to express their opinions[193]. Employee and Management - The total number of employees at the end of the reporting period is 423, with 240 from the parent company and 183 from major subsidiaries[187]. - The professional composition includes 281 production personnel, 11 sales personnel, 54 technical personnel, 10 financial personnel, and 67 administrative personnel[187]. - The company has established a competitive compensation system to attract and retain talent, including a long-term equity incentive plan for key personnel[188]. - The company has implemented a comprehensive training system to enhance employee skills and promote sustainable development[189]. - The company has a focus on internal promotions and career development for its management team[170]. Future Outlook - The company aims to achieve a significant increase in market share over the next few years through strategic initiatives[162]. - The company plans to accelerate new product development and optimize existing production technologies, focusing on differentiated competition in the fine chemical market[119]. - The company recognizes the high potential of the petrochemical industry, particularly in high-end specialty chemicals and high-performance materials, which are crucial for strategic emerging industries[117]. - The company will enhance sales channels and innovate sales strategies to increase market coverage, focusing on building a professional sales team and strengthening domestic and international sales channels[120].

Financial Performance - The company's revenue for Q1 2024 was ¥134,549,472.48, a decrease of 42.34% compared to ¥233,350,600.29 in the same period last year[5] - Net profit attributable to shareholders was ¥8,001,565.58, down 76.32% from ¥33,794,308.43 year-on-year[5] - Basic earnings per share decreased by 77.42% to ¥0.07 from ¥0.31 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 134.55 million, a decrease of 42.4% compared to CNY 233.35 million in the same period last year[20] - Net profit for Q1 2024 was CNY 8.77 million, a decline of 74.0% from CNY 33.81 million in Q1 2023[22] - Earnings per share for Q1 2024 were CNY 0.07, compared to CNY 0.31 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities was ¥14,005,060.14, reflecting a decline of 67.50% compared to ¥43,097,793.56 in Q1 2023[5] - Cash inflow from operating activities was CNY 134.56 million, down 38.3% from CNY 217.94 million in Q1 2023[24] - The total cash outflow from operating activities was ¥120,559,575.85, down from ¥174,837,490.23 in the previous year[25] - The net cash flow from investment activities was ¥78,848,297.85, recovering from a negative cash flow of ¥21,164,979.71 in Q1 2023[25] - The net increase in cash and cash equivalents for Q1 2024 was ¥93,440,251.52, a substantial rise from ¥22,466,667.14 in Q1 2023[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,660,791,990.90, a decrease of 1.35% from ¥1,683,513,672.39 at the end of the previous year[5] - The company's total liabilities decreased to CNY 275.24 million from CNY 307.15 million year-over-year, a reduction of 10.4%[21] - Total liabilities decreased by 49.20% in short-term borrowings, reflecting a reduction in bank loans[11] - Total equity increased to CNY 1,385.55 million from CNY 1,376.36 million, reflecting a growth of 0.7%[21] Research and Development - The company reported a significant drop in R&D expenses, which were ¥3,672,063.05, down 54.10% from ¥7,999,391.16 in the same period last year[12] - Research and development expenses for Q1 2024 were CNY 3.67 million, a decrease of 54.0% compared to CNY 8.00 million in the previous year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,140[14] - The largest shareholder, Liansheng Chemical Group Co., Ltd., holds 52.78% of shares, totaling 57,000,000 shares[14] Inventory and Receivables - Accounts receivable increased to ¥72,232,662.22 from ¥56,422,428.53, representing a growth of about 28%[18] - Inventory decreased to ¥87,019,265.49 from ¥115,782,015.47, a reduction of approximately 25%[18] Other Financial Activities - The company reported a financial income of CNY 4.23 million, compared to a financial expense of CNY 2.48 million in the same period last year[21] - The company received tax refunds amounting to CNY 7.21 million, slightly down from CNY 8.63 million in Q1 2023[24] - The company is actively exploring new product development and market expansion strategies[15] Audit and Reporting - The company did not undergo an audit for the Q1 2024 report[26] - The report was released by the board of directors on April 26, 2024[26]

浙江联盛化学股份有限公司 董事、监事和高级管理人员持有和变动本公司股份管理制度 浙江联盛化学股份有限公司 董事、监事和高级管理人员持有和变动 本公司股份管理制度 第一章 总 则 第一条 为加强浙江联盛化学股份有限公司（以下简称"公司"）对董事、监事 和高级管理人员持有及变动本公司股份的管理工作，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司收购管理办法》《上市公司股东、董监高减持股份的若干规定》《上 市公司董事、监事和高级管理人员所持本公司股份及其变动管理规则》《深圳证 券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》《深圳 证券交易所上市公司自律监管指引第 10 号——股份变动管理》等法律、法规、 规范性文件以及《浙江联盛化学股份有限公司章程》（以下简称《公司章程》） 的有关规定，并结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事、监事和高级管理人员及本制度第二十一条 规定的自然人、法人或其他组织持有及买卖本公司股份的管理。 第三条 公司及董事、监事和高级管理人员在买卖公司股份及其衍生品种前， 应知悉《公司法》《 ...

浙江联盛化学股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第 三届董事会第十三次会议，审议通过了《关于以自有资产抵押向银行申请综合授 信额度的议案》，同意公司以自有资产抵押向银行申请综合授信额度，现将相关 事项公告如下： 一、融资及抵押情况概述 根据公司业务发展需要，为满足日常生产经营资金需求，公司拟以自有资产 位于浙江头门港经济开发区东海第三大道 9 号作为抵押物，向中国银行股份有限 公司和中国工商银行股份有限公司共同申请总额不超过 10,000 万元人民币的综 合授信额度。本次拟申请的授信额度不等于公司实际发生的融资金额，最终授信 额度、期限等以银行实际审批为准。公司董事会授权董事长或其书面授权委托人 在上述授信额度及担保条件范围内办理相关手续，并签署相关法律文件。 公司本次资产抵押申请综合授信事项不构成关联交易，亦不构成重大资产重 组，根据《深圳证券交易所创业板股票上市规则》和《浙江联盛化学股份有限公 司章程》等相关规定，本次资产抵押申请综合授信事项在公司董事会审批权限内， 无需提交股东大会审议。 二、本次抵押资产基本情况 证券代码：301212 证券简称：联盛化学 公告编号：2 ...

浙江联盛化学股份有限公司 防范控股股东、实际控制人及其他关联方资金占用管理制度 浙江联盛化学股份有限公司 防范控股股东、实际控制人及其他关联方资金占用管理制度 第一条 为规范浙江联盛化学股份有限公司（以下简称"公司"）与控股股 东、实际控制人及其他关联方的资金往来，避免公司控股股东、实际控制人及其 他关联方占用公司资金，根据《中华人民共和国公司法》《中华人民共和国证券 法》、《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等有关法律、法规、规范性文件以及《浙江联盛化学股份有限公司章程》的有关 规定，制定本制度。 第二条 公司与控股股东、实际控制人及其他关联方之间的所有资金往来均 适用本制度。 第三条 本制度所称资金占用包括经营性资金占用和非经营性资金占用。 经营性资金占用是指控股股东、实际控制人及其他关联方通过采购、销售等 生产经营环节的关联交易产生的对公司的资金占用。 非经营性资金占用是指公司代控股股东、实际控制人及其他关联方垫付工 资、福利、保险、广告等费用和其他支出，代控股股东、实际控制人及其他关联 方偿 ...

浙江联盛化学股份有限公司 董事会秘书工作细则 第一条 为了促进浙江联盛化学股份有限公司（以下简称"公司"）规范化运 作，充分发挥董事会秘书的作用，加强董事会秘书工作的指导，根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以 下简称《证券法》）、《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律、法 规、规范性文件以及《浙江联盛化学股份有限公司章程》（以下简称《公司章 程》）的有关规定，制定本细则。 第二条 公司设董事会秘书一名，由公司董事、副总经理、财务负责人或 者公司章程规定的其他高级管理人员担任，对公司和董事会负责，负责公司股 东大会和董事会会议的筹备、文件保管以及公司股东资料的管理，办理信息披 露事务等事宜，为信息披露事务负责人。 第三条 董事会秘书应当遵守《公司章程》，承担法律法规及《公司章 程》对公司高级管理人员所要求的义务，享有相应的工作职权，并获取相应报 酬，对公司负有忠实和勤勉义务，不得利用职权为自己或他人谋取利益。 第四条 董事会秘书应当熟悉履职相关的法律法规、具备与岗位要求相适 应的职业操守、具 ...

浙江联盛化学股份有限公司 2023 年财务决算报告 一、2023 年度公司整体经营情况 2023 年度，浙江联盛化学股份有限公司（以下简称"公司"）全年实现营业 总收入为 662,015,730.44 元，同比下降 36.41%；归属于上市公司股东的净利润 为 71,112,773.72 元，同比下降 61.13%。 二、2023 年度公司财务报告审计情况 公司 2023 年度财务报表已经容诚会计师事务所（特殊普通合伙）审计，并 出具了容诚审字[2024]100Z0830 号无保留意见的审计报告。 三、2023 年度主要财务数据和指标 | 单位：元 | | --- | | 应收款项融资 | 39,955,192.24 | 0.00 | 100% | | --- | --- | --- | --- | | 预付款项 | 3,457,048.74 | 11,280,917.36 | -69.35% | | 其他应收款 | 2,400,034.72 | 5,968,570.67 | -59.79% | | 存货 | 115,782,015.47 | 107,264,309.16 | 7.94% | | 其他流动资产 ...

证券代码：301212 证券简称：联盛化学 公告编号：2024-017 浙江联盛化学股份有限公司 浙江联盛化学股份有限公司（以下简称"公司"）根据中华人民共和国财政部 （以下简称"财政部"）颁布的《企业会计准则解释第 17 号》（财会〔2023〕21 号）的要求变更会计政策。公司本次变更事项属于根据国家统一的会计制度要求 或法律法规作出的变更，该变更事项无需提交公司董事会和股东大会审议，现将 本次变更情况公告如下： 一、本次会计政策变更概述 （一）变更的原因及日期 2023 年 10 月 25 日，财政部颁布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），其中规定"关于流动负债与非流动负债的划分"、"关于供应 商融资安排的披露"和"关于售后租回交易的会计处理"的内容自 2024 年 1 月 1 日起施行。 公司根据上述文件规定的起始实施日，开始执行上述新会计政策。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （三）变更后采用的会计政策 关于会计政策变更的公 ...

浙江联盛化学股份有限公司 2023 年度监事会工作报告 2023 年度，浙江联盛化学股份有限公司（以下简称"公司"）监事会根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）及《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等法律法规的要求，结合公司实际情况， 遵循《浙江联盛化学股份有限公司章程》（以下简称"《公司章程》"）、《浙 江联盛化学股份有限公司监事会议事规则》等相关制度，诚实守信、勤勉尽责， 本着对股东负责的精神，认真履行职责，依法行使职权，按时召开监事会会议， 并通过参加公司股东大会、列席公司董事会会议等多种形式，对会议的召开程序、 公司经营活动、财务状况、重大决策及董事、高级管理人员履行职责的合法、合 规性进行有效的监督，在促进公司规范运作和维护全体股东的利益方面起到了积 极作用。 一、2023 年度监事会会议召开情况 2023 年度，公司召开 4 次监事会，会议的召集、召开和表决程序、决议内容 均符合法律、法规、规范性文件及《公司章程》的规定，会议召开具体情况如下： | 序号 | 会议届次 | | 召开日期 ...